Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported financial results for the three and six months ended June 30, 2017.
Maxim analyst Jason Kolbert slashes his price target on shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to $5.
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced that it has received a $15 million milestone payment from Janssen Research & Development, LLC.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination …
In a research report released Friday, Chardan analyst Madhu Kumar upgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to a Neutral rating, without providing a price …
News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors running for the hills and have left shares …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported financial results for the three months ended September 30, 2016.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D …
